Melissa M Berrien-Elliott

List of Publications by Year
in descending order

48 papers	2,646 citations	257450 24 h-index	276875 41 g-index
50 all docs	50 docs citations	50 times ranked	4010 citing authors

#	Article	IF	Citations
1	Phase 1/dose expansion trial of brentuximab vedotin andÂlenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood, 2022, 139, 1999-2010.	1.4	17
2	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, 2022, 139, 1177-1183.	1.4	41
3	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine, 2022, 14, eabm1375.	12.4	49
4	Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood, 2022, 139, 1670-1683.	1.4	57
5	A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells. Molecular Therapy - Oncolytics, 2022, 24, 585-596.	4.4	5
6	Flow cytometry-based ex vivo murine NK cell cytotoxicity assay. STAR Protocols, 2021, 2, 100262.	1.2	8
7	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 3339-3350.	7.0	26
8	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Bloodâ€"Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clinical Cancer Research, 2021, 27, 3744-3756.	7.0	69
9	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clinical Cancer Research, 2021, 27, 4859-4869.	7.0	33
10	A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. Cancer Immunology Research, 2021, 9, 1071-1087.	3.4	36
11	Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo. Blood, 2021, 138, 194-194.	1.4	0
12	Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer. Blood, 2021, 138, 3825-3825.	1.4	1
13	Memory-like natural killer cells for cancer immunotherapy. Seminars in Hematology, 2020, 57, 185-193.	3.4	48
14	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. Cancer Discovery, 2020, 10, 1854-1871.	9.4	83
15	Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. Cell Reports, 2020, 31, 107720.	6.4	40
16	Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. Developmental Cell, 2020, 53, 229-239.e7.	7.0	63
17	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood, 2020, 136, 2308-2318.	1.4	133
18	Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Science Translational Medicine, 2020, 12, .	12.4	57

#	Article	IF	Citations
19	CD56 regulates human NK cell cytotoxicity through Pyk2. ELife, 2020, 9, .	6.0	30
20	531â€…AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies. , 2020, , .		0
21	MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity, 2019, 51, 479-490.e6.	14.3	39
22	Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT). Blood, 2019, 134, 1954-1954.	1.4	19
23	Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. Blood, 2019, 134, 3307-3307.	1.4	9
24	Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors. Blood, 2019, 134, 869-869.	1.4	1
25	Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses. Blood, 2019, 134, 3237-3237.	1.4	6
26	Abstract 1546: The CD30/CD16A bispecific innate immune cell engager AFM13 elicits heterogeneous single-cell NK cell responses and effectively triggers memory-like (ML) NK cells. , 2019, , .		2
27	Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development. Blood, 2019, 134, 2464-2464.	1.4	0
28	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood, 2018, 131, 2515-2527.	1.4	307
29	MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Research, 2018, 78, 3510-3521.	0.9	39
30	Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function. Blood, 2018, 132, 1271-1271.	1.4	0
31	Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcÎ³RIIIa-Triggered Responses. Biology of Blood and Marrow Transplantation, 2017, 23, 398-404.	2.0	48
32	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood, 2017, 129, 473-483.	1.4	147
33	Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathologica, 2017, 133, 61-77.	7.7	72
34	CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. Journal of Clinical Investigation, 2017, 127, 4042-4058.	8.2	236
35	Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes. Cancer Immunology Research, 2016, 4, 1016-1026.	3.4	15
36	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine, 2016, 8, 357ra123.	12.4	621

#	Article	IF	Citations
37	Abstract LB-326: Identification of novel recurrent mutations in follicular lymphoma. , 2016, , .		0
38	Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming. Blood, 2016, 128, 550-550.	1.4	0
39	Improving natural killer cell cancer immunotherapy. Current Opinion in Organ Transplantation, 2015, 20, 671-680.	1.6	44
40	Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research, 2015, 3, 116-124.	3.4	32
41	Human Cytokine-Induced Memory-Like Natural Killer Cells. Journal of Innate Immunity, 2015, 7, 563-571.	3.8	81
42	MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation. Journal of Immunology, 2015, 195, 2806-2817.	0.8	44
43	Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 101-101.	1.4	4
44	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. Blood, 2015, 126, 574-574.	1.4	2
45	Neuropilin-1 Expression Is Induced on Tolerant Self-Reactive CD8+ T Cells but Is Dispensable for the Tolerant Phenotype. PLoS ONE, 2014, 9, e110707.	2.5	21
46	Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance. Journal of Leukocyte Biology, 2014, 96, 397-410.	3.3	9
47	Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance. Cancer Research, 2013, 73, 605-616.	0.9	41
48	CD8⁺T Cell Exhaustion During Persistent Viral Infection is Regulated Independently of the Virus-Specific T Cell Receptor. Immunological Investigations, 2013, 42, 204-220.	2.0	10